Bioprosthetic Valve Fracture: In-Depth Techniques and Updated Data

David J. Cohen, M.D., M.Sc.

Director of Cardiovascular Research
Saint Luke's Mid America Heart Institute

Professor of Medicine
University of Missouri-Kansas City

Disclosures

Grant Support/Drugs

- Daiichi-Sankyo
- Astra-Zeneca
- Merck

Grant Support/Devices

- Edwards Lifesciences
- Medtronic
- CSI
- Abbott Vascular
- Boston Scientific
- Corvia

Consulting/Advisory Boards

- Medtronic
- Edwards Lifesciences
- Amgen

Valve-in-Valve TAVR



- VIV TAVR is an effective alternative to redo surgery in high or intermediate risk patients with failing tissue valves.
- However, VIV TAVR can be problematic with small surgical bioprostheses because of further reduction in the effective orifice leading to high residual gradients.

Impact of Surgical Valve Size on 1-Year Mortality



VIVID Registry

- 459 pts with failed surgical bioprostheses treated with ViV TAVR (59% balloon expandable, 41% self-expanding)
- Patients stratified based on size of original surgical valve
  - *Small ≤ 21 (n=133)*
  - *Medium 22-24 (n=176)*
  - *Large ≥ 25 (n=139)*
- Small surgical valve independently associated with 1-year mortality (HR 2.04, p=0.02)

Dvir D, et al. JAMA 2014;312:162-170

Patient P.M.

- 71 y.o. man with bioprosthetic valve degeneration
- Underwent AVR/CABG x 3 in 2007 (19 mm Magna)
- Did well until late 2015 when he began to notice increasing DOE and fatigue
- Echo: normal LV and RV size, LVEF 65%, aortic valve gradient 60 mmHg (peak 79 mmHg) with trivial AI
- Referred for redo AVR vs. TAVR→ felt to be high risk due to patent grafts and proximity of RV to sternum→ ViV TAVR

#19 Magna Valve: True Internal Diameter 17 mmHg
Planned for 23 mm CoreValve EVOLUT

Baseline Hemodynamics



Mean gradient = 63 mmHg AVA 0.8 cm2



Valve Implant

Aiming for High Implant

Post-TAVR and Post-Dilation



Mean gradient = 44 mmHg AVA 1.0 cm2

In-Lab Conversation (Paraphrased)

- *IC*: This isn't good. We still have almost as high a gradient as when we started
- *CTS*: I know how to treat this. We can break the surgical valve.
- *IC*: What??? Are you crazy?
- *CTS*: I heard about it at a meeting recently. A surgeon from LA said he had done it a few times
- *IC:* Really? I still think you're crazy. Just like when you told us that transcarotid TAVR was a good idea.

Here's what you'll need…



- 1 True Dilatation, ATLAS, or ATLAS-GOLD Balloon (Bard)→ Kevlar wrapped
- 1 60 cc luer lock syrine filled with dilute contrast
- 1 PTCA indeflator
- 1 high-pressure stopcock

** <u>Disclaimer</u>: This is 100% off-label use and may require exceeding balloon RBP considerably*

And here's the set-up…





High Pressure Post-Dilation with 20 mm True Balloon



Post- 20 mm True Balloon (16 atm)



Mean gradient = 18 mmHg AVA 1.9 cm2

How Valves Fracture



CT Reconstruction

23 mm CoreValve in a 21 mm Magna



Single Fracture Point

Sewing Ring Otherwise Intact

Valves that can and cannot be fractured

To date, the only valves that cannot be fractured are:

Trifecta (St. Jude)
Hancock II (MDT)
Avalus (MDT)*

Manufacturer/ Brand	Valve Size	Bard TRU Balloon Fracture/Pressure	Bard Atlas Gold Balloon Fracture/Pressure	Appearance After Fracture
St. Jude Trifecta	19 mm 21 mm	NO NO	NO NO	
St. Jude Biocor Epic	21 mm	YES / 8 ATM	YES / 8 ATM	
Medtronic Mosaic	19 mm 21 mm	YES / 10 ATM YES / 10 ATM	YES / 10 ATM YES / 10 ATM	
Medtronic Hancock II	21 mm	NO	NO	
Sorin Mitroflow	19 mm 21 mm	YES / 12 ATM YES / 12 ATM	YES / 12 ATM YES / 12 ATM	
Edwards MagnaEase	19 mm 21 mm	YES / 18 ATM YES / 18 ATM	YES / 18 ATM YES / 18 ATM	
Edwards Magna	19 mm 21 mm	YES / 24 ATM YES / 24 ATM	YES / 24 ATM YES / 24 ATM	

1. Balloons sized 1 mm larger than valve size.
2. Medtronic Mosaic and Sorin Mitroflow have no metal in ring therefore appearance after fracture unchanged.

Allen KB, et al. Ann Thorac Surg 2017

Some Valves can also be "Remodeled"

Valves that can be fractured	Valves that can be remodeled	Neither
Biocor Epic	C-E Standard	Avalus
Magna/Magna Ease	C-E SAV	Hancock II
Mitroflow	Perimount (older generation)	
Mosaic	Trifecta	
Perimount (newer generation)		
Inspiris		

Chhatrwialla AK, et al. Circ Cardiovasc Interv. 2018, *in press*

BVF Clinical Series

Structural Heart Disease

Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement

Adnan K. Chhatriwalla, MD; Keith B. Allen, MD; John T. Saxon, MD;
David J. Cohen, MD, MSc; Sanjeev Aggarwal, MD; Anthony J. Hart, MD;
Suzanne J. Baron, MD, MSc; Danny Dvir, MD; A. Michael Borkon, MD

Background—Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) may be less effective in small surgical valves because of patient/prosthesis mismatch. Bioprosthetic valve fracture (BVF) using a high-pressure balloon can be performed to facilitate VIV TAVR.

Methods and Results—We report data from 20 consecutive clinical cases in which BVF was successfully performed before or after VIV TAVR by inflation of a high-pressure balloon positioned across the valve ring during rapid ventricular pacing. Hemodynamic measurements and calculation of the valve effective orifice area were performed at baseline, immediately after VIV TAVR, and after BVF. BVF was successfully performed in 20 patients undergoing VIV TAVR with balloon-expandable (n=8) or self-expanding (n=12) transcatheter valves in Mitroflow, Carpentier-Edwards Perimount, Magna and Magna Ease, Biocor Epic and Biocor Epic Supra, and Mosaic surgical valves. Successful fracture was noted fluoroscopically when the waist of the balloon released and by a sudden drop in inflation pressure, often accompanied by an audible snap. BVF resulted in a reduction in the mean transvalvular gradient (from 20.5±7.4 to 6.7±3.7 mm Hg, $P<0.001$) and an increase in valve effective orifice area (from 1.0±0.4 to 1.8±0.6 cm^2, $P<0.001$). No procedural complications were reported.

Conclusions—BVF can be performed safely in small surgical valves to facilitate VIV TAVR with either balloon-expandable or self-expanding transcatheter valves and results in reduced residual transvalvular gradients and increased valve effective orifice area. **(*Circ Cardiovasc Interv*. 2017;10:e005216. DOI: 10.1161/CIRCINTERVENTIONS.117.005216.)**

Key Words: aortic stenosis ■ bioprosthesis ■ transcatheter aortic valve replacement

Downloaded from http://circinterventions.ahajournals.org/ by guest on July 12, 2017

Transcatheter aortic valve replacement (TAVR) has become an alternative, less invasive treatment option for patients at intermediate or high risk for surgical aortic valve replacement.[1-4] The treatment of failed surgical bioprosthetic valves with valve-in-valve (VIV) TAVR has also been reported; however, patients with small surgical bioprosthesis (≤21 mm in diameter) undergoing VIV TAVR seem to have higher residual gradients and higher late mortality than other patients undergoing VIV TAVR.[5] Because VIV TAVR further decreases the orifice of the previously implanted surgical bioprosthesis, these findings suggest that patient/prosthesis mismatch (PPM) may play an important role in outcomes after VIV TAVR.[6]

See Editorial by McElhinney

PPM has typically referred to a situation in which the effective valve area after surgical valve replacement is less than that of a normal human valve.[7] In the aortic position, severe PPM is defined by an indexed effective orifice area of $<0.65\ cm^2/m^2$, and the incidence of severe PPM after surgical aortic valve replacement ranges between 2% and 20%. A recent meta-analysis suggested that predictors of PPM after surgical aortic valve replacement include older age, female sex, hypertension, diabetes mellitus, renal failure, larger body surface area, larger body mass index, and the utilization of a bioprosthesis.[8] Furthermore, the presence of PPM is prognostically important because PPM results in higher valve gradients and increased perioperative and overall mortality.[8]

Isolated cases have previously been reported in which a bioprosthetic valve ring has been fractured using a high-pressure balloon inflation to facilitate VIV TAVR, to allow further expansion of the transcatheter valve to maximize the effective orifice area and minimize PPM.[9-11] We have previously reported results from bench testing that outline which bioprosthetic valves can and cannot be fractured.[12] In this article, we describe procedural results from a series of consecutive cases in which bioprosthetic valve fracture (BVF) was performed.

- 20 consecutive patients* from 7 US centers treated with bioprosthetic valve fracture at the time of ViV TAVR (8 at MAHI)
- Mean age 76 years; mean STS-PROM 8.4%
- Valves treated: Mitroflow, Perimount, Magna/Magna-Ease, Biocor Epic/Epic-Supra, and Mosaic
- Treated with both self-expanding (n=12) and balloon expandable (n=8) TAVR valves
- 15/20 underwent BVF <u>after</u> TAVR valve deployed

* 75 cases in full series as of 6/1/18

Mean Gradient



Effective Orifice Area



* Measurements only available for pts treated with BVF after ViV TAVR

BVF Complications (n= 75 pts/21 centers)

- 2 minor strokes
- 1 chordal tear → moderate-severe MR (Mitraclip)
- 1 severe AI from disruption of TAVR valve → treated with second valve-in-valve
- No in-hospital death
- No coronary occlusion
- No annular rupture (clinical or subclinical)
- No PPM

* 75 cases in full series as of 6/1/18

When to Consider BVF

- Patients with small or intermediate sized surgical bioprostheses
  - *True ID ≤ 21 mm in prior studies*
- Pts with high residual gradients following VIV TAVR
  - *Severe PPM generally defined as a residual mean gradient ≥ 20 mmHg*
  - *Our threshold is much lower*
- ? All patients undergoing VIV TAVR
  - *By facilitating optimal THV expansion, BVF/BVR might improve leaflet function and THV durability regardless of surgical valve size or residual gradient*

When not to Fracture

- Surgical valves that cannot be fractured/remodeled
  - *Hancock II, Avalus*
- Concern for coronary artery/STJ obstruction
  - *Assess virtual THV to coronary distance*
  - *Consider coronary protection or BASILICA if < 3mm*
- Small STJ or LVOT
  - *Ensure that the anatomy can accommodate the balloon used to perform BVF*
  - *Assess calcium burden*

Summary: BVF for ViV TAVR

- For patients with small bioprosthetic valves who are high risk for re-do AVR, BVF/BVR may offer a “solution” to high residual gradients after ViV implantation
- Most contemporary surgical valves can be fractured (or at least remodeled)
- Clinical experience to date suggests the procedure is generally safe (although not entirely risk-free)
- Unresolved questions
  - *Timing of BVF (pre vs. post-TAVR)→ impact on safety and long-term TAVR valve durability*
  - *Should all ViV procedures undergo BVF (even with a low gradient) to allow for better TAVR valve geometry and function*